Cardiomyocytes Market Size

Cardiomyocytes Market size is expected to reach USD 12 Billion by the end of 2036, growing at a CAGR of 10% during the forecast period, i.e., 2024 -2036. In the year 2023, the industry size of cardiomyocytes was USD 5 Billion. The market is thriving on the back of the rising incidence of cardiovascular diseases in the world. According to research an estimated 7% of men and around 4.5% of women suffer from heart-related diseases. The heart's rhythmic beating is regulated by cardiomyocytes, which are the cells that produce contractile force in an intact heart. Hence, increasing the demand for cardiomyocyte therapies in the world.

In addition to these, factors that are believed to fuel the market growth of the cardiomyocytes market include the growing geriatric population. Research shows that an estimated 771 million individuals worldwide were 65 years of age or older in 2022, making up about 10% of the world's population. This increases the demand for cardiomyocyte therapies as older people are more susceptible to cardiovascular diseases.

Frequently Asked Questions (FAQ)

The major factors driving the growth of the Cardiomyocytes market are the rising incidence of cardiovascular diseases in the world, rising investments in research and development, expanding adoption of cell therapy, and increase in healthcare expenditure and reimbursement policies.

The market size of cardiomyocytes is anticipated to attain a CAGR of 10% over the forecast period, i.e., 2024-2036.

The major players in the market are AstraZeneca, Novartis, Pfizer, Roche, Johnson & Johnson, Merck & Co., Inc., Bayer, Abbott Laboratories, Bristol Myres, Cytiva, and others.

The Human iPSC-derived Cardiomyocytes segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

Cardiomyocytes Market Size